Bridge City Capital LLC Buys 11,509 Shares of iRadimed Corporation $IRMD

Bridge City Capital LLC grew its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 19.4% during the fourth quarter, Holdings Channel reports. The firm owned 70,854 shares of the medical equipment provider’s stock after purchasing an additional 11,509 shares during the period. iRadimed makes up approximately 2.0% of Bridge City Capital LLC’s investment portfolio, making the stock its 7th largest position. Bridge City Capital LLC’s holdings in iRadimed were worth $6,893,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its holdings in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares in the last quarter. Quarry LP acquired a new position in shares of iRadimed in the 3rd quarter valued at $40,000. CWM LLC increased its holdings in shares of iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Finally, USA Financial Formulas acquired a new position in shares of iRadimed in the 4th quarter valued at $82,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $100.38, for a total value of $501,900.00. Following the transaction, the chief executive officer directly owned 2,235,000 shares in the company, valued at $224,349,300. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 62,500 shares of company stock valued at $5,794,878. Company insiders own 36.80% of the company’s stock.

iRadimed Price Performance

Shares of iRadimed stock opened at $93.60 on Friday. The firm’s fifty day simple moving average is $90.89 and its 200-day simple moving average is $95.87. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 51.15 and a beta of 0.91. iRadimed Corporation has a 12 month low of $55.11 and a 12 month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Analysts anticipate that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is 43.72%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, iRadimed presently has an average rating of “Buy” and an average target price of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.